Myasthenia gravis: Frequently asked questions

John A Morren; Yuebing Li

doi:10.3949/ccjm.90a.22017

Myasthenia gravis: Frequently asked questions

Cleve Clin J Med. 2023 Feb 1;90(2):103-113. doi: 10.3949/ccjm.90a.22017.

Authors

John A Morren¹, Yuebing Li²

Affiliations

¹ Staff, Neuromuscular Center, and Program Director, Neuromuscular Medicine Fellowship, Neurological Institute, Cleveland Clinic, Cleveland, OH; Associate Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH.
² Neuromuscular Center, Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, OH; Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH Liy@ccf.org.

PMID: 36724914
DOI: 10.3949/ccjm.90a.22017

Abstract

Myasthenia gravis is a disorder of neuromuscular junction transmission, the result of antibodies against the post-synaptic aspect of the neuromuscular junction. Its clinical hallmark is fatigable weakness of skeletal muscles, which tends to vary in location and severity among patients. It is treated with pyridostigmine, immunotherapy, and thymectomy. Treatment is often individualized according to disease severity, antibody status, comorbidities, and other factors. This review uses a question-and-answer format to provide up-to-date, high-yield, clinically relevant information on myasthenia gravis.

Publication types

Review

MeSH terms

Humans
Muscle Weakness / etiology
Muscle, Skeletal
Myasthenia Gravis* / diagnosis
Myasthenia Gravis* / therapy